Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

FitRx vs Vytora Health

Two GLP-1 desks, one scoreboard. We put FitRx and Vytora Health head-to-head on the published Brief Score — the same six factors, scored the same way.

No. 106 · Grade C

FitRx

Visit FitRx Full brief →

FDA warning letter, February 2026 — issued to FitRX, LLC dba FitRx. See the FDA's warning letter database.

vs
Higher Brief ScoreNo. 16 · Grade B+

Vytora Health

Visit Vytora Health Full brief →

The verdict

Vytora Health takes this head-to-head.

Vytora Health scores 87 to 72 on our six-factor Brief Score — A rare accredited desk that pairs brand-name access with fair mid-market compounded pricing across all 50 states.

That doesn't make FitRx a bad call — it's best for readers who want insured patients seeking brand-name glp-1 access with compounded fallback. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
46
85
Supply Reliability
80
87
Transparency
88
88
Access Breadth
86
90
Clinical Oversight
76
88
Track Record
60
82
FitRxBrief Score 72 · 87Vytora Health

Price, coverage & the tracker

FitRxVytora Health
Brief Score72/100 (C)87/100 (B+)
SemaglutideFrom $151/mo (quarterly plan, compounded)$150/mo
TirzepatideNot disclosed$200/mo
CoverageAll 50 statesAll 50 states
Brand-name accessYesYes
Oral / sublingualInjection onlyInjection only
On the trackerNewnew to the tracker, no prior readingStableprice stable

FitRx: New to the tracker on 1 August 2026. The published line reads From $151/mo (quarterly plan, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

Vytora Health: $150 sema / $200 tirz nationwide; LegitScript-certified with brand-name access.

Not sold on either?

CoreAge Rx tops the whole ranking at 94/100.

The steadiest desk in the ranking: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.